{"preliminary_commentary":{"by_channel":{"x_thread":29,"youtube":8,"podcast":1,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07075185\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"inMMyCAR","nct_id":"NCT07075185","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=inmmycar-nct07075185. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"inMMyCAR","arms":[{"description":"Drug: KLN-1010 specified dose given once","label":"KLN-1010","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2042-05","type":"ESTIMATED"},"conditions":["Multiple Myeloma in Relapse","Myeloma Multiple","Multiple Myeloma Progression","Neoplasms by Histologic Type","Neoplasm","Hemostatic Disorders","Vascular Disorder","Paraproteinemias","Blood Protein Disorders","Hematologic Disease and Disorders","Lymphoproliferative Disorders","Immunoproliferative Disorders","Immune System Disease","Gene Therapy"],"enrollment":{"count":70,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"KLN-1010","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-28","lead_sponsor":"Kelonia Therapeutics, Inc.","official_title":"A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-03","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence and severity of treatment-emergent adverse events (TEAEs), including dose-limiting toxicities (DLTs), and/or establish the recommended Phase 2 Dose","timeFrame":"Up to 15 years from dosing of KLN-1010"}],"references":[],"start_date":{"date":"2025-07-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT07075185"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/inmmycar-nct07075185"}